药效团
药物发现
口服活性
计算生物学
小分子
钥匙(锁)
虚拟筛选
化学
凋亡抑制因子
细胞凋亡
立体化学
计算机科学
生物
生物化学
程序性细胞死亡
体外
计算机安全
作者
Le Wang,George A. Doherty,Andrew S. Judd,Zhi‐Fu Tao,T. Matthew Hansen,Robin R. Frey,Xiaohong Song,Milan Bruncko,Aaron R. Kunzer,Xilu Wang,Michael D. Wendt,John A. Flygare,Nathaniel D. Catron,Russell A. Judge,Chang H. Park,Shashank Shekhar,Darren C. Phillips,Paul M. Nimmer,Morey L. Smith,Stephen K. Tahir
标识
DOI:10.1021/acsmedchemlett.9b00568
摘要
Abstract Herein we describe the discovery of A-1331852, a first-in-class orally active BCL-XL inhibitor that selectively and potently induces apoptosis in BCL-XL-dependent tumor cells. This molecule was generated by re-engineering our previously reported BCL-XL inhibitor A-1155463 using structure-based drug design. Key design elements included rigidification of the A-1155463 pharmacophore and introduction of sp3-rich moieties capable of generating highly productive interactions within the key P4 pocket of BCL-XL. A-1331852 has since been used as a critical tool molecule for further exploring BCL-2 family protein biology, while also representing an attractive entry into a drug discovery program.
科研通智能强力驱动
Strongly Powered by AbleSci AI